Interventions need to be tailored to the patient's current level and stage of BP SA. 6. The key difference between SSD and IA is that in SSD distress is due to somatic symptoms (e.g., pain) while in IA distress is primarily due to fear of serious medical condition (e.g., mild pain elicits fear that patient has cancer). 7. Specialized psychotherapy and pharmacologic treatments deliveted by an interdisciplin ary team can be effective treatments for SSD and IA.
INTRODUCTION
Integration of medical and mental health care is essential for the effective treatment of patients with somatic symptom disorder (SSD) or illness anxi ety (IA). The world's best models of care for these disorders are based on an integrated approach. Unfortunately, in many countries, patients with SSD and IA often fall through the cracks between primary care and mental health and do not fi nd much help in either specialty. Such a chasm is often widened by a lack of communication between dis ciplines, leading to increased patient suffering, dis ability, and ineffective use of health care resources. 1 This creates a public health problem, and in some countries, an alarming one, given the prevalence of individuals with these disorders in medical settings.
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A number of challenges in the diagnosis and treatment of SSD and IA contribute to this public health problem. While the diagnosis of SSD or IA rightfully motivates a primary care provider (PCP) to make a referral to a behavioral health specialist (e.g., psychiatrist, psychologist, or a clinical social worker who specializes in psychosomatic medi cine), many patients will not accept a psychiatric diagnosis and therefore will not follow the PCP's recommendations, making it impossible for them to get the specialized treatment they need. Another difficulty is the continuous need for reassessment and differentiation between the symptoms that require medical treatment (e.g., cancer) and symp toms that require SSD/IA-focused treatment. Yet another challenge is clinician burnout. Patients with these disorders often present with unending suffer ing and complaints despite numerous investigations and treatments, making clinicians feel helpless. Patients often feel that their symptoms are not taken seriously and are dismissed as "not real" or "unim portant" by the physician, clinic staff, and/or their family and friends. This adds to their despair, further exacerbating the vicious cycle of distress and somatic symptoms. Finally, in many countries, the very organization of health care and medical education is organ-or system-focused, making the treatment of brain-body conditions quite challenging as these disorders fall through the gap in the psychiatry medicine divide. However, patients with SSD and IA can be treated effectively, and working with these patients can be a deeply rewarding experience for both the PCP and behavioral health clinicians.
The approaches presented in this chapter are aimed at overcoming these challenges and help ing multidisciplinary teams to care for SSD and IA patients in primary care or integrated care settings. They are based on the integration of (1) the best practices and available guidelines for t�eating these conditions in the world today, (2) evidence from research studies on diagnosis and treatment, and (3) the latest translational research relevant to the understanding of the etiology and treatment of SSD and IA. Research on SSD and IA has been expand ing rapidly. Usually, it takes years for the insights from basic neuroscience to be implemented into clinical care and tested in large randomized control trials and dissemination studies. To diminish this time gap, this chapter presents approaches that are informed by the latest findings in translational neu roscience relevant to SSD and IA. Box 16.1 summa rizes key points that are discussed in this chapter.
CLINICAL PRESENTATION AND ETIOLOGY
The nosology of somatic symptoms and illness fears is complex and has changed considerably in recent years. Numerous diagnostic labels are used to describe somatic symptoms somatoform, multi somatoform, abridged somatoform, bodily distress syndrome, psychophysiologic, psychosomatic, functional, or somatic symptom disorders; soma tization; medically unexplained, psychogenic, or idiopathic symptoms. In a medical office, a patient with somatic symptoms may be diagnosed with fibromyalgia, irritable bowel syndrome, or chronic fatigue syndrome, as criteria for these diagnoses are based on the similar list of symptoms. Terms also periodically change to newer ones that haven't yet acquired the pejorative connotation of"not real" or "imagined," a connotation that is understandably distressing for patients.
Recently, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 3 replaced the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
4 diagnoses of somatoform, somatization, and pain disorders with the diagnosis of SSD. While the new criteria have some advantages (e.g., the diagnosis no longer requires a certain arbitrary number of symptoms as was the case with DSM-IV's somatization disorder), the primary disadvantage is that the criteria now include both the somatic symptoms and "excessive worry or distress about somatic symptoms," mak ing it difficult to distinguish patients who primarily have somatic symptoms from those who primar ily have a fear about what their somatic symptoms mean (e.g., pain vs. worry that pain is a sign of undi agnosed cancer, the latter being a symptom of IA). Because the distinction between these two dimen sions is important for treatment planning, we focus separately on somatic symptoms and IA.
Somatic Symptoms Clinical Presentation
Patients with somatic symptoms present with bodily symptoms (e.g., pain, fatigue, gastrointesti nal [ GI] symptoms) resulting in distress and impair ment. If a medical problem is present, the severity of distress or disability significantly exceeds what would be expected. Estimates of lifetime prevalence of somatic symptoms depend on the diagnostic cri teria used. Studies that have used more inclusive criteria report a 12-month prevalence of somatic symptoms of up to 30% in the general population 2 and up to 49% in primary care clinics. 5 Women are more frequently affected than men. 2 Patients with somatic symptoms are often frus trated by the lack of a medical diagnosis. Because these patients consult many different physicians in pursuit of a diagnosis and treatment, the result is often fragmented patient care, unnecessary repeti tive tests, and costly, potentially dangerous surger ies. Ordering multiple diagnostic tests increases the
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likelihood of an abnormal fi nding that is medically inconsequential, which, despite reassurance from the physician, leads to the patient's concern that findings are being ignored. For example, multiple studies of asymptomatic populations revealed that structural spine or knee abnormalities on mag netic resonance imaging did not predict pain.
•
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Additional rounds of tests and procedures lead to further delays in the initiation of treatments focused on somatic symptoms.
A somatic reaction to an acute stressor usually resolves on its own or when the PCP offers psycho education and reassurance. Somatic symptoms asso ciated with chronic or early developmental stressors require a specialized treatment. Because timely diagnosis and treatment are important for prevent ing the transformation of acute somatic symptoms into chronic ones, exploration of psychosocial stressors at the initial primary care visit is essential. Unfortunately, in most current medical practices, psychological stressors are often considered last, after all medical reasons for the symptoms have been explored, leading to signifi cant delays in estab lishing the diagnosis of SSD. Clues to the diagnosis of SSD include: (1) symptoms that change bodily location from one month to the next, (2) neurologic complaints that do not follow the anatomic distri bution of nerve pathways, (3) somatic symptoms that fluctuate with varying levels of stress on macro (scale of months and years) and/or micro (scale of minutes, hours, days) levels, and (4) amplified affec tive or experiential aspect of a symptom (e.g., report a of pain rating of "20" on a 0-10-point scale or a report of pain level that does not correspond to the patient's observed level of functioning).
Patients with chronic somatic symptoms are often disconnected from their emotions, alex ithymic (i.e., have difficulty expressing emotions verbally), have problems tolerating conflicting emo tions, or have difficulty differentiating between vari ous emotions they experience. Typically, when asked about feelings in an emotional situation, these indi viduals either don't respond or talk about thoughts, actions, or somatic sensations. Research suggests these difficulties are often associated with a history of early interpersonal trauma, insecure attachment, or growing up in non-optimal interpersonal envi ronments (e.g., when a parent is depressed or physi cally ill, emotionally abusive, or overprotective), or cultural norms that restrict emotional expression; all of these factors can impede socioemotional develop ment. 2 ·8 As adults, many patients tend to feel lonely or are highly sensitive interpersonally, perceiving others as hurting, abandoning, or unavailable.
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Though some patients may seem socially distant, this demeanor may represent the defensive stance of someone who craves interpersonal closeness but fears abandonment and rejection. Lack of help from physicians is often perceived by an emotionally frag ile patient as yet another abandonment, which exac erbates the vicious cycle of interpersonal distress and somatic symptoms. In a subgroup of patients, emotional confl ict kept outside of awareness can also manifest as somatic symptoms.
Comorbidity and Differential Diagnosis
An appropriate medical workup is essential for ruling out an underlying medical disorder in patients with somatic symptoms. 2 • 9 Although a patient may present with exclusively somatic com plaints, comorbid psychiatric disorders among those with som;tic symptoms are common. In one study, 54% of the patients with somatic symptoms had comorbid depression, anxiety, or both.10 In another study, over 76% of primary care patients with depression presented somatically. 11 Careful temporal plotting of somatic and mood symptoms as well as assessment of which symptoms cause most distress and disability helps to determine which diagnosis is primary. Once the primary dis order is effectively treated, somatic symptoms may dissipate. Somatic symptoms (especially chronic pain) may be particularly comorbid with atypical depression, characterized by mood reactivity (i.e., patient's mood may be brightened by interaction with the physician) and heightened interpersonal sensitivity. Somatic symptoms should not be con fused with factitious disorders (e.g., Munchausen syndrome) or malingering. Unlike malingers who manipulate society by reporting fictitious symp toms, or factitious and Munchausen patients, who unconsciously long to be treated as an ill patient, patients with somatic symptoms genuinely experi ence bodily distress.
Etiology
Somatic symptoms may result from different etio logic pathways. Recent research suggests that genetic predisposition, multigenerational transmis sion of trauma through psychological or epigenetic mechanisms, exposure to early stressors, or a non optimal early interpersonal environment can all influence development of the nervous and immune systems. These factors can contribute to difficulty differentiating somatic and emotional cues from the body, problems with the regulation of somatic and emotional distress, and chronic hyperactivation of central neural circuits (i.e., central sensitization). 2,s These obstacles to healthy development may predis pose a person to experiencing emotional distress primarily somatically.
Illness Anxiety
Clinical Presentation
IA refers to the irrational, excessive fear or belief that one has a serious illness based on a misinterpre tation of physical signs and symptoms. Individuals with IA do not experience sustained relief after being reassured by a PCP that no serious illness is present. IA can also affect a patient with an underly ing medical condition if worry about a stable illness becomes so excessive as to impair the patient's well being and functioning. In the DSM-5 , IA with no or only mild somatic symptoms is referred to as illness anxiety disorder. IA, however, is also a criterion for DSM-5 SSD. Previously, in DSM-IV, IA was a dis tinct diagnosis known as hypochondriasis.
Issy Pilowsky in 1967 identifi ed three central aspects of hypochondria: fear of illness, disease conviction, and bodily preoccupation .. These three aspects may occur in any combinati�n, giving the patient a distinctively different clinical presenta tion. For example, a patient with a high degree of illness fear may actually avoid going to see a doctor, scared that the doctor will confi rm the presence of a dreaded disease. In fact, avoidance o( medical care is a dangerous and often underrecognized symptom of IA that causes patients to miss available life-saving diagnostic procedures and treatments. However, in another presentation of IA, a patient with a high degree of disease conviction and lower fear may pur sue a diagnosis with relentless persistence, berating physicians who fail to repeat a full battery of tests and becoming enraged by medical science's inabil ity to help. A patient with high bodily preoccupation but lesser conviction may present to the physician with a variety of inexplicable physical complaints and appear to have SSD. Other obsessional traits may be present: a fear that terrible harm might come to loved ones; intrusive, horrifi c images; obsessive thoughts about dirt or germs; an anxiety-driven need for perfection, order, or symmetry; troubling sexual images; and scrupulous moral or religious concerns. Common compulsions include excessive body checking, searching for medical information, and talking about their medical symptoms and fears with others.
Transient hypochondriasis implies illness fears that last weeks or months and do not become chronic, typically abating on their own (e.g., medi cal students often develop transient hypochondria sis after learning about a new horrifi c disease). In IA, disease fears persist for at least 6 months. The course of IA may wax and wane in severity, exacerbated by various stressors in the patient's life.
Estimates of the prevalence of IA depend on the restrictiveness of the criteria. A meta-analysis of 47 independent samples suggested that IA was found in up to 13% in the general population and up to 8% in primary care settings.12 In a study of specialty clinics in England, the prevalence of health anxiety assessed by self-report questionnaire was 25% in neurology, 21 % in respiratory medicine, 19.5% in gastroenterol ogy, 19% in cardiology, and 18% in endocrinology. l 3
Comorbidity and Differential Diagnosis
Common conditions that might present with IA include panic disorder, major depression, and gen eralized anxiety disorders. The similarities between IA and obsessive-compulsive disorder have impor tant treatment implications as the methods of treat ing obsessive-compulsive disorder are also effective for hypochondriasis.
Etiology
The etiology of IA is unclear but likely includes psy chological, cultural, and biological components. Psychologically, IA may serve as a window into unre solved emotional issues or earlier developmental confl icts. Culturally, IA and bodily concerns may be an acceptable mode of expressing emotional stress. One current theory emphasizes that hypochondri acs have a tendency to amplify, augment, and mis interpret normal bodily sensations, experiencing interoceptive cues as more intense and noxious. t Hypochondriacs are physiologically hyperreactive to external stimuli. 15 The neurochemical underpin nings of these constitutional differences in the IA patient may be similar to the serotonergic imbalance seen in OCD, or to the noradrenergic imbalances seen in panic disorder, with similar neural circuity abnormalities observed in all three conditions. 
Somatic Symptoms Versus Illness Anxiety
While somatic symptoms and IA often co-occur, most patients suffer primarily from either somatic symptoms or IA. Different treatment approaches to these conditions have been suggested (e.g., treat ment studies with serotonergic pharmacotherapy typically report greater improvement in IA than in somatic symptoms). 1 7 To determine which treat ment approach to emphasize, the clinician should determine whether somatic symptoms or obses sional anxiety about health are central. We recom mend using direct questions about distress and functional interference from somatic symptoms versus from illness worries as described in the Columbia Somatic Symptoms & Illness Anxiety Ratio Scale. 1 8 This scale should be administered after rapport is established and after the clinician validates the patient's symptoms; posing a question about anxiety too early may communicate to the patient that the symptoms are not taken seriously.
IDENTIFICATION AND TREATMENT IN INTEGRATED HEALTH CARE SYSTEMS
Overall Approach and Principles
The following are essential principles of effective care for patients with SSD and IA in integrated set tings and relevant recommendations for organiza tion of care.
Complete Abandonment of Mind-Body Dualism
For centuries, the division between the body and the mind/brain has been at the core of philosophy and mentality in many cultures around the world. The biopsychosocial approach proposed by Engel in the 1970s 19 aimed to reverse this dualism by emphasizing that everything that is psychological is biological, and everything that is biological is psy chological. Bio, psycho, and social are just different levels of inquiry at which health can be considered from molecular, through organ, individual, family, to societal levels and beyond. (For example, an emo tion of anger involves fl uctuation of neural circuits and neurotransmitters in the brain, muscle tension, and perhaps a behavior of clenching a fi st or yelling). This paradigm shift away from dualism to full accep tance of the biopsychosocial approach is necessary for treating SSD and IA, for organizing effective care, and for explaining these diagnoses to patients. Since duality is deeply rooted in our culture, eradi cating this dualism in everyday patient care is a pro cess that will initially require an effort on the part of clinicians and health care organizations. 
Emotions and Stress Are Universally Experienced on a Somatic (Bodily) Level
Patients with somatic symptoms are often perceived by others (including health care professionals) as "them" versus "us," and as having mysterious, inexpli cable symptoms. However, any emotion is a somatic experience, involving physiologic changes in our bod ies. For example, feeling lack of energy for days after a breakup 1'7ith a romantic partner, or experiencing an increas· e in the rate of breathing when we are anx ious are natural somatic reactions to stress. There is an individual variability in the tendency to somatize, in the intensity and duration of bodily distress, as well as in the ability of a person to regulate this distress. Highlighting to patients the universality of somatiza tion will help them feel less alienated and more accept ing of the bidirectional relationship between emotions and somatic symptoms. This is a crucial component of treatment. Sincere acceptance and understanding of the patient's suffering goes a long way.
Similarly, fears of having a serious disease and of death are universal phenomena. The duration, dis tress, and dysfunction associated with these fears distinguish pathologic from nonpathologic IA.
Level and Stage of a Patient's Biopsychosocial Awareness Informs All
Aspects of Care
Treatment of SSD and IA will depend on the degree to which a patient accepts the diagnosis, which, in turn, will depend to a large degree on whether the patient adopts a biopsychosocial understanding of health, disease, and his/her symptoms. We call this a biopsychosocial awareness (BPSA (1) precontemplation, (2) contemplation, (3) prepara tion, (4) action, and (5) maintenance.
A patient presenting to primary care can be at any stage (temporal) and level (unidirectional vs. reciprocal concept of biopsychosocial interaction) of BPSA (see Fig. 16 .1 and the example in Table  16 .1). If SSD or IA is suspected, one of the primary goals of evaluation is determining the patient's cur rent stage and level of BPSA in order to tailor appro priate interventions.
Levels of BPSA
In the CS-BPSA model levels describe the degree of awareness of the bidirectional relationship between emotions and somatic symptoms (see Fig. 16 .lB). Level A indicates recognition that so 111 atic symptoms can unidirectionally affect mood or functioning, level B indicates recognition that psychological stressors or emotions can unidirectionally influence the body and lead to somatic symptoms, and level C indicates awareness of the bidirectional relationship between "bio" and "psychosocial." If a patient presents with no BPSA, usually level A is the easiest to reach fi rst. To facilitate this, clinician may ask: "Has your pain affected your sleep?" or "How does pain make you feel emotionally?" or "It must be difficult to pick up your two-year-old son when you have such severe back pain; how has that affected your relationship with him?" Though unidirectional, level A is a step toward full BPSA. Level B refers to awareness of the reverse relationship: stress/emotion/brain affect the body and may produce or exacerbate somatic symp toms. Level B understanding will range in depth, for example, from acknowledging that lack of sleep can increase pain, to realization that anger at a spouse leads to bouts of back pain. Stressors that are more "somatic" (sleep, appetite) are more easily integrated into Level B BPSA than emotions, blends of emotions, confl icting emotions, or interpersonal issues. Full BPSA (Level C) implies acceptance of the complete bidirectionality of bio and psychosocial factors, includ ing the vicious circle that this relationship creates (e.g., the realization that "anger at a spouse elicits my back pain, which in turn makes my anger even stronger").
Stages of Change in BPSA
A patient at the precontemplation stage (see Fig.  16 .lA and example in Table 16 .1) presents with complete mind-body dualism. These patients are usually focused on finding only a biological expla nation for somatic symptoms and are not open to considering BPSA. At this stage, the most challeng ing task for a clinician is to stay at the patient's level of understanding, carefully assessing whether the patient is ready to move to the contemplation stage (i.e., to consider the association between stressors and somatic symptoms). However, pushing a patient along the stages too fast may only alienate the patient and harm the doctor-patient relationship, making the patient feel misunderstood, depressed, or angry. The main tasks at the precontemplation stage are acknowledging the patient's suffering and symptoms and establishing a cooperative patient clinician working alliance. Hearing another person (especially a clinician) reiterate the patient's main complaint can be a powerful validation. The clini cian may say: "You have been in a lot of pain for many years." Open-ended questions about symptoms and stressors are more helpful than statements. Instead of saying "Your GI problems can be related to the stress oflosing your job," the clinician may ask, "Did your GI symptoms increase in the last month? What else was going on in your life at that time?" Patients are more likely to incorporate new understanding of the link between stressors and symptoms into their view of the world if they arrive at those conclusions by themselves.
The clinician's best stance at the contemplation stage is to invite the patient to be on a team of inves tigators regarding his or her condition. This demon strates interest in the patient's experience, validates the presence of somatic symptoms, and models a genuine curiosity regarding links between somatic symptoms and experiences. After all, with no labo ratory findings to confirm SSD, we can never have 100% certainty about the diagnosis. However, we can
•-PsychoSocial Realization that GI symptoms start with increase of anxiety, and then fear of GI cancer increases anxiety and GI symptoms "Caused by anxiety-scheduled appointment with psychiatrist; but no recognition of panic attacks affecting worsening relationship with children due to avoidance of activities Aware of the following vicious cycle and acts on breaking it: fatigue and lack of energy is associated with feeling alone and memories of being abandoned by parents; fatigue leads to withdrawal from social interaction with friends and boyfriend, which leads to deepening of the feelings of aloneness. When feeling this way patient now reaches out to friends, boyfriend, and/or psychotherapist, which alleviates both feelings of abandonment and fatigue. 
Using the CS-BPSA Model
The CS-BPSA Rating form (see Table 16 .1) can be used during diagnosis and treatment planning and for tracking the patient's progress. The opti mal zone of intervention during the moment-to moment interactions with patients is usually one level or stage away from the patient's current BPSA. Jumping over a level or stage can alienate a patient and lead to a rupture in the patient-clinician rela tionship. A patient may be at different levels and stages of BPSA regarding different symptoms (see the examples in Table 16 .1). Progress in treatment and symptom alleviation, however, often happens before a full BPSA is achieved, and some patients may become asymptomatic without ever achieving compete BPSA. Many patients with somatic symptoms or IA feel a lack of control over their bodies and lives, which increases their distress and exacerbates somatic symptoms. Engaging patients as part of an integrated care team is essential, as it restores their feelings of agency and promotes self-awareness and responsibility. Asking open-ended questions (e.g., "What are your goals?" "What treatments do you believe will help?" "What are your fears?"), inviting the patient's feedback, and developing a treatment plan in an interactive way is therapeutic. It is also important to let patients know that they can and will see different members of an integrated care team. A BPSA culture also includes recognition of the burnout and stress among health care professionals. Patients suffering from somatic symptoms or IA are particularly difficult to treat. Professionals caring for these patients often develop feelings of helplessness and frustration, as well as empathic emotional and bodily reactions. Processing these reactions with col leagues, in a group setting, can prevent burnout, con tribute positively to clinicians' heath, and promote BPSA-informed self-awareness. Onsite training for clinic staff in mind-body techniques (e.g., mindful ness training or relaxation techniques) helps their well being and enhances the BPSA culture of the clinic.
Language is an integral aspect of culture. It is important to explore which terms for somatic symp toms and IA are currently best accepted by the local community of patients and health care professionals. At the same time, patients and providers need to be educated about the actual meaning of tbe terms they may hear (e.g., that psychosomatic does not mean "it's all in your head"). While adopting acceptable terms, it is important to not avoid or be apologetic about using the term psychological, as doing so indirectly communicates that the term has derogatory mean ing and implicitly promotes mind-body dualism. In fact, it is best not to divide factors into medical/bio logical and psychological. Currently, in many cultures, referring to the "brain" and the "nervous system" provides an easily understandable bridge between the "bodily" and "psychological" as people tend to readily accept that the brain is involved in psycho logical processes, yet at the same time is an organ of our body, which controls other bodily functions.
The Quality of Patient-Clinician Relationship Is an Essential Treatment Component
Patients with somatic symptoms and IA often crave care and interpersonal connection. Many of them grew up in challenging interpersonal environments and continue to experience interpersonal distress and loneliness, expecting others to hurt, ignore, or abandon them. 8 Repeated experiences of hav ing their symptoms discredited as imaginary rein force their distrustful interpersonal worldview and exacerbate interpersonal sensitivity and somatic symptoms. Continuously fearing rejection, they are particularly attuned to nonverbal and implicit inter personal cues. Unfortunately, clinicians often react negatively to patients suffering with somatic symp toms and IA. One study reported that the single greatest factor that led a physician to suspect hypo chondriasis in a patient was the degree of frustra tion in treating that patient. 21 Videotapes of PCPs interviewing somatoform pain patients revealed split-second facial expressions of disgust. Breaking the vicious cycle of interpersonal distress and exac erbation of somatic symptoms is highly therapeu tic. In fact, a recent study showed that a physician's patient-oriented interview style affected activity in pain-modulating brain regions.
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Patient-clinician communication styles vary by team member and country. If maintaining pro fessional distance with a patient is a cultural norm, it might be advisable to modify this enculturated style toward a more personable, warm, and engaged approach, as professional distance might be per ceived as lack of care by a sensitive patient. Being lis tened to and validated by all team members (i.e., front desk to medical and specialist staff) are vital human needs that frequently are unmet among patients with somatic symptoms and IA. Giving patients their voices, as much as possible, will start reversing their experience of feeling invalidated/not heard by physi cians, team members, friends, and family.
Primary care clinicians, and ultimately the team, are advised to be transparent with somatic symptoms or IA patients about what diagnoses were ruled out and why, and to cite specific research that is being considered when thinking about the patient. Sharing the team's reasoning and treatment plan with the patient shows the thoughtfulness that went into making a recommendation, helps a patient experience being cared for, and models the biopsychosocial way of thinking.
Including Translational Research Findings in Education of Patients and Clinicians
Symptoms of SSD and IA are often surrounded by a mystique and raise the questions "Are they real? How do they magically appear in the absence of any detectable peripheral damage or disease?" Unfortunately, in many cultures ps y chosomatic still means "not real" or "imagined." Neuroscience research indicates that validity of somatic symptoms should no longer be questioned: Musculoskeletal pain, GI, neurologic, and other bodily symptoms can be experienced without findings of periph eral abnormalities. Numerous studies showed that somatic symptoms are associated with dysregula tion of neural circuits in the brain; changes in brain neurochemistry and immune functions; emotions and stress that can modulate physical pain on a neural level and can affect health in humans and animals; and the quality of the early environment, which affects development of the brain and other systems of the organism.
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24 These findings help demystify SSD and IA syndromes, providing both patients and their treatment teams tangible infor mation that can decrease anxiety caused by "unex plained symptoms, for unknown reasons, with uncertain future," as well as increase the clinician's confidence when recommending psychosocial (i.e., neuromodulating) treatments for somatic symp toms, as these treatments affect neural circuits and neurotransmitter systems in the brain. Research based psychoeducation is critical.
Organization of Care
The current state of SSD and IA treatment varies among countries.
2 While several countries have guidelines for the treatment of specific symptoms (e.g., chronic pain or fibromyalgia), specialized guidelines for the organization of care and treat ment of SSD and IA patients are rare. Germany 25 and the Netherlands 26 issued comprehensive guide lines based on the systematic review of the latest evi dence. The Dutch Multidisciplinary Guideline for Medically Unexplained Symptoms, commissioned by the Dutch Ministry of Public Health, Welfare, and Sport, was published in 2011. 26 In 2012, the third edition of the Guidelines for Management of Patients with Non-specific, Functional, and Somatoform Bodily Complaints was issued in Germany. 25 It was developed by a special taskforce organized by the German College of Psychosomatic Medicine and the German Society of Psychosomatic Medicine and Medical Psychotherapy, which con sisted of the representatives of 28 medical and psy chological societies who reached a multidisciplinary consensus on assessment and treatment guidelines. Recommendations presented here are based on the integration of those guidelines and research con ducted since they were published.
Systems Approach to Establishing
Integrated Care for SSD and IA
Overwhelming evidence points to the need for radical reorganization of fragmented health care approaches to SSD and IA. This reorganization needs to be in accord with the evidence from neuroscience for the crucial role of the central nervous system in health and disease. International consensus suggests that the following organization of care is essential for the effective identification, diagnosis, and treatment of SSD and IA: (1) creation of specialized psycho somatic clinics, (2) integration of primary care and specialty psychosomatic/behavioral health care, and (3) a stepped-care approach to treatment.
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The following steps (or levels) of care are suggested:
(1) multidisciplinary collaborative care within the primary care clinic; (2) multidisciplinary care in primary care clinic in combination with outpatient psychosomatic/BHS treatment (e.g., individual and/or group psychotherapy); and (3) intensive psy chosomatic _ day-treatment and inpatient programs in collaboration with primary care. Implementation of these changes may seem unrealistic in the current climate of the primary care medicine/mental health divide, especially given the shortage of health care resources in many countries. However, the new model of inte grated care offers hope. Studies demonstrate that an integrated approach not only results in effec tive treatment of somatic symptoms and IA, but also dramatically decreases health care costs and disability, as well as inefficient use of resources and physician-patient time. Patients with somatic symptoms and IA represent a large proportion of visits in primary care, neurology, pain, GI, other medical clinics, and emergency departments. The cost of such inefficient care is enormous. For example, medical care costs of SSD in the United States in 2002 were estimated at $256 billion, an amount nearly double the $132 billion cost of diabetes care that year. 1 The overall societal costs almost double health care costs as they include disability and decreased productivity, which are highly prevalent among untreated SSD and IA patents.
27
The cost and resource effectiveness of providing specialized psychosomatic care was documented in a number of studies in several countries. 27 For example, in Chile, a randomized controlled trial of Brief Family Intervention (one to three sessions) among 256 somatoform patients decreased health care cost at the I-year-follow-up by 97% versus no change in the treatment-as-usual control group (p < .0001, d = .8).
28 (See Chapter 27: Best Practice for Family-Centered Health Care: A Three-Step Model for additional information about a fam ily therapy approach.) Among 216 patients with fibromyalgia in Spain, psychoeducation interven tion significantly decreased pain, improved global and physical functioning, and demonstrated cost utility of the intervention versus usual care. 29 In a Canadian emergency department study, treating SO patients with medically unexplained symptoms with a short-term dynamic therapy (averaging 3.8 sessions and $438/patient) reduced emergency department visits by 69% and costs by $910/ patient. 30 In Germany, treatment for somatic symp toms comprising 10 weekly group sessions con ducted by the PCP and psychosomatic specialists/ BHS decreased the severity of somatic symptoms, psychosocial distress, and the number of visits to a PCP. 31 (See Chapter 28: Group Interventions in Integrated Care Settings for additional informa tion about groups.) In the Netherlands, a random ized controlled trial of a collaborative-ca_ re model, which included training for primary care clinicians and a psychiatric consultation for patients with per sistent medically unexplained symptoms, showed a 58% decrease in somatic symptoms and a significant reduction in health care use.
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In a number of countries, includirfg the United States, the health care payers (e.g., Medicare and private health insurance companies) have initi ated and promoted transition to accountable care models (enabling collaborative multidisciplinary care as opposed to the traditional fee-for-service model), which are being rewarded financially. 33 (See Chapter 6: Financing Integrated Care Models.) This shift makes the resource-intensive in-depth multi disciplinary assessments described in this chapter not only financially feasible but advantageous.
Specialized psychosomatic services that col laborate with other medical and psychiatric depart ments in a hospital are essential. Has this been done? In Germany, almost every university hospi tal has a specialized psychosomatic department. In 2007, there were 151 of them throughout the coun try, treating about 50,000 patients.
2 Psychosomatic clinic staff members provide education to other medical specialties regarding the diagnosis and treatment of somatic symptoms and IA, which contributes to implementation of a BPSA culture in a hospital or health care system and helps move patients along the steps of care. In Denmark, the staff of the Research Clinic for Functional Disorders and Psychosomatics gradually educated their medi cal colleagues throughout the hospital in recogniz ing the somatic symptoms and IA and facilitating somatic symptoms/IA-focused treatments. 34 An innovative collaborative care program in Germany brings psychosomatic care to the workplace, which increases early detection and intervention for somatic symptoms and IA.
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While transition to electronic medical records may have increased efficiency in providing health care for many other diagnoses, this is not yet the case with SSD and IA. Providers tend not to enter SSD and IA diagnoses into the electronic medical record. Those who do may enter any of the terms used to described somatic symptoms and IA, hindering reli able tracking of these conditions. Reluctance to enter a diagnosis of SSD or IA into the electronic medical record may occur for many reasons, one of which is the limited availability of specialized treatments for these disorders. Systematic reorganization of care for SSD and IA should include educating providers about the importance of accurately documenting and tracking these patients' diagnosis and treatment progress. At a primary care clinic level, the implementa tion of a stepped-care approach would include the following:
1. Creating a multidisciplinary team of a PCP, a BHS, a physical therapist, a mind-body clinician, and a care manager 2. Establishing collaboration with a psychosomatic and/or behavioral health specialist in the area 3. Training all staff in the BPSA model and in effective clinician-patient communication 4. Developing regular multidisciplinary case conferences S. Identifying psychoeducational materials about somatic symptoms and IA (handouts, videos, internet resources) 6. Organizing time-limited or ongoing psychoeducational groups 7. Setting up mind-body therapy groups or establishing collaboration with existing ones 8. Setting up a system for periodic check-ins with patients by a care manager.
Necessary steps include establishing close col laboration between primary care and a special ized psychosomatic clinic/other BHS providers. Psychosomatic medicine/behavioral health clini cians can participate in multidisciplinary evalua tions in primary care to (1) contribute to diagnosis and treatment planning, (2) facilitate continuity of care if transition to specialized treatment is needed, and (3) provide additional expertise in treating par ticularly challenging cases.
Care Pathways
The level of care recommended for a particular patient depends on ( 1) the severity of somatic symp toms and illness anxiety; (2) the level and stage of the patient's BPSA; (3) medical and psychiatric comorbidities; (4) acute versus chronic stressors (e.g., bereavement within a month of death of a loved one vs. years of loneliness); and (5) develop mental predisposing factors (e.g., well-developed emotional awareness and no early developmental traumas vs. a profound lack of emotional awareness and growing up in an emotionally abusive environ ment). The PCP's involvement at every step is cru cial for the continuity of care (see Fig. 16 .2 for an overview of the care pathways).
Evaluation for Somatic Symptoms and Illness Anxiety
Up to 49% of visits to primary care clinics are asso ciated with somatic symptoms, 5 and other patients may have psychosocial factors contributing to their medical conditions. Therefore, any initial visit to pri mary care would benefi t from psychosomatic assess ment. Self-report somatic symptoms screening scales (Tables 16.2 and 16. 3) can be administered to all patients presenting to a clinic, and patients scor ing high on these measures can then be seen by both primary care and behavioral health practitioners at an early stage of evaluation. As there is no clear con sensus that any one or several screening instruments are better than other(s), individual practices will need to make their own choices depending on their context and goals. These scales are particularly help ful in picking up multiple somatic symptoms that are common is SSD and help differentiate between SSD and IA, for which patients usually present with one primary complaint.
• 36 •
37 Box 16.2 summarizes the issues to be addressed during the initial evalua tion by the interdisciplinary team. Because somatic symptoms often require additional medical workup or review of medical records, the initial evaluation may take more than one visit. Evaluation visits to rule out other medical causes and arrive at an SSD or IA diagnosis should be closely spaced.
Somatic symptoms and IA occurring exclusively in the context of another psychiatric disorder usually dissipate once the underlying condition is treated. When referring a patient to psychiatry/psychology, it is important to stress a collaborative team-oriented treatment plan, saying: "Dr.B and other members of the team will work together to help you; you will see Dr. B and other members of the team on a regular basis" to minimize the chance that the patient will feel dismissed or handed over. If somatic symptoms and anxiety persist beyond successful treatment of the other neuropsychiatric condition, the steps rec ommended for primary SSD/IA should be followed.
In the case of mild somatic symptoms/anxiety, acute stressors, and/or a high stage ofBPSA, patients can be effectively treated in primary care with psy choeducation (by a BHS, primary care clinician, or nurse), with reassurance from the PCP, time-lim ited individual or group sessions by the BHS, and/ or a mind-body group. In the case of moderate to severe symptoms, a chronic or complicated course, developmental predisposition, and/or a low BPSA level or stage, a comprehensive multidisciplinary evaluation is recommended ( Fig. 16.2 ).
Comprehensive Multi-Disciplinary Evaluation (CMDE)
Usually, the CMDE is conducted in a primary care clinic or in an integrated practice. If it occurs in a psychosomatic clinic, the primary care team takes part in the evaluation. The CDME is both assess ment and the fi rst stage of treatment. Headed by a PCP and BHS, a team relevant to the patient's somatic symptoms is assembled, and a care man ager is assigned. A thorough critical review of medi cal records for any potentially missed diagnoses or necessary diagnostic assessments is conducted. 9 Fragmented care by multiple physicians actually puts somatic symptoms and IA patients at risk for missed diagnoses. In a semistructured diagnos tic interview with the patient (see Table 16 .2), the clinician comprehensively reviews all symptoms and systems and then conducts a Comprehensive Symptoms and Experiences Timeline (CSET ) interview (Box 16.3). If it is not feasible for the PCP and the BHS to interview a patient together, one clinician conducts parts of CDME, the other team members are informed about the details of the inter view, and the patient is made aware of this. •psychosomatic psychodynamic, interpersonal, and CBT approaches depending on SS vs IA ratio, chronicity, stressors, and developmental factors Abbreviations: CBT, cognitive behavioral therapy; CSET, comprehensive symptoms and experiences timeline; IA , illness anxiety; LCSW, licensed clinical social worker; MBSR, mindfulness-based stress reduction; MD, doctor of medicine; MDD, major depressive disorder; MH, mental health; NP , nurse practitioner; PA, physician assistant; PC, primary care; pt, patient; PT. physical therapy; SS, somatic symptoms; sx, symptoms; tx, treatment While a time-consuming procedure, CSET is both a diagnostic tool and a powerful intervention to enhance BPSA, identify stressors and develop mental factors, and engage the patient in treatment planning. Though devoting so much time to one patient is not customary for PCPs in many coun tries, this investment of time actually proves time saving for future primary care visits. 31 While ideally CSET is done by medical staff (physician or nurse practitioner) and BHS together, in many settings this it is not feasible. In this case, after the physician or nurse practitioner goes over medical aspects of evaluation, the BHS can do the CSET part, making sure that the patient is aware that the medical staff will be informed of the data collected and that the diagnosis and treatment plan will be made by the multidisciplinary team.
CSET consists of plotting all somatic symptoms and life experiences on a whole-life timeline in order to explore, together with the patient, the patterns of temporal relationships between them (see details in Box 16.3). CSET helps unaware patients discover links between somatic symptoms and stressors, which is a fundamental step in treatment of somatic symptoms and IA.
CMDE involves continuous exploration of the biopsychosocial interactions on macro (whole life), intermediate (daily/weekly), and micro (moment to-moment) levels. Conducting CMDE over sev eral visits allows exploration of changes in somatic symptoms and the patient's thoughts and feelings since the previous appointment. Sharp changes in somatic symptoms (e.g., increase or decrease of pain) during a session should be immediately fol lowed up with exploration of what the patient has been feeling or thinking. The Micro Symptoms and Experiences Timeline (MSET) (see Box 16.3) provides unique in-the-moment opportunities for increasing BPSA insight, which often takes prior ity over collecting information. Additionally, self report measures of early life and current life stressors (see examples of measures in Table 16 assess stressors and convey the importance of these factors for health. The team case conference for consensus diagno sis and treatment planning is followed by a feedback and treatment planning session with the patient. Presenting SSD and IA diagnoses to a patient in a BPSA-sensitive way is challenging. In addition to BPSA-informed communication (previously described), the following components of feedback session are recommended:
1. Validation of symptoms (somatic symptoms and/or anxiety regarding somatic symptoms) 2. Delivery of the diagnosis with a clear explanation of the meaning of SSD or IA labels 3. Asking the patient to explain his or her understanding of the diagnosis to catch any misunderstanding (repeat this during treatment, as relapses in misunderstanding are common) 4. Conveying that treatments exist and getting better is possible, though it may take time 5. A metaphor coined by Dr. Stanley Fahn, a neurologist at Columbia University, of "computer hardware problem versus software problem" is helpful in explaining to a patient that his or her symptom is a result of a problem in the functioning ("software") of the nervous system versus structural ("hardware") damage or disease. 6. Communicate the team's commitment to help the patient and highlight the value of a multidisciplinary approach.
Interactive treatment planning facilitates the patient's commitment to the plan. Practical steps might include the following:
1. Writing out the patient's goals (e.g., decrease pain and loneliness) 2. Clarifying known ways to achieve these goals (e.g., increase activity, decrease opioicjs, learn to cope with interpersonal stressors) 3. Describing treatments that can help achieve the goals (e.g., favorite physical activity; medication adjustment, initiation of psychotherapy) 4. Outiining the specifi c steps the patient chooses to take 
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Both psychodynamic/interpersonal psycho therapy 3 6 · 57 · 5 8 and cognitive-behavioral therapy (CBT) 59 have been shown to alleviate somatic symptoms to various degrees, 25 with some evi dence pointing to psychodynamic therapies in particular leading to functional improvement.
60
Psychotherapeutic strategies shown to be most helpful are those that focus on emotions and interpersonal relationships, teaching the indi vidual to read somatic emotion cues from the body and to express and regulate emotions in the interpersonal environment. Working through developmental traumas and stress has also been shown to be a key element of treatment. 60 Initial engagement might employ expressive psychother apies, such as music, art, and/or dance/movement psychotherapies, as these are powerful ways to engage the patient's emotions at a nonverbal level, enhancing the development of self-awareness, symbolization, expression, and regulation of emo tions. Because patients with somatic symptoms often have a detached relationship with their own bodies, therapeutic techniques that help develop nonthreatening bodily awareness can be par ticularly helpful, such as relaxation techniques, breathing therapies, mindfulness meditation (e.g., Mindfulness-Based Stress Reduction), or biofeed back. The combination of individJ.:ial and group psychotherapy may be particularly helpful for those who suffer from somatic symptoms. Patients with more severe somatic symptoms may require intensive multimodal day-treatment or inpatient programs that incorporate these approaches. 25·61·62 These programs were shown to be effective and to help normalize the functioning of neural circuits in patients with somatic symptoms, as measured by functional magnetic resonance imaging. 
Treatment Approaches to IA
Optimal treatment consists of integrated care, psychotherapy, and pharmacotherapy. 14 Both indi vidual CBT and group CBT have been shown to be effective in number of studies.
64 A dose-response relationship was observed in CBT treatments, with a greater number of sessions associated with greater improvement. This suggests that the relationship with the therapist might be an important factor that facilitates change. 64 Acceptance and commit ment group therapy can reduce IA symptoms. 65 Mindfulness-based interventions, such as deep breathing, progressive muscle relaxation, and meditation, are helpful in reducing symptoms and learning new ways to relate to one's body.
66 SSRis (fl uoxetine, paroxetine) can alleviate IA, 67·6 8 with higher doses of fluoxetine (40-80 mg) and of par oxetine (40-50 mg) considered to be more effec tive than lower doses. While there haven't been any controlled trials comparing the efficacy of an SSRI versus an SNRI for illness anxiety, one study of depressed patients 69 that compared an SNRI and an SSRI revealed that the SNRI duloxetine had greater efficacy for symptoms of psychomotor retardation, general somatic symptoms, and sexual problems, while the SSRI sertraline led to greater improvement in agitation, anxiety symptoms, and hypochondriasis. Long-term follow-up studies suggest that improvement in IA is sustained com parably for those treated with either CBT or SSRI therapy. 70 
Organization of Treatment of SSD and IA in Integrated Care Model
For patients with mild somatic symptoms or IA, for those resistant to psychosomatic care, or if there are no BHS/psychosomatic providers in the area, mul tidisciplinary SSD/IA treatment can be arranged in integrated care settings. Regular (as opposed to symptom-based) appointments, as determined by individual patient needs, are recommended. 2·25 A team of clinicians relevant to the patient's somatic symptoms and level of BPSA is assembled (e.g., PCP, individual and/or group psychotherapists, physical therapist, expressive psychotherapists, mind-body psychotherapistsi nutritionist and sleep specialists, if needed). A group intervention conducted by the PCP and BHS/psychosomatic specialist together was shown to be effective for somatic symptoms 31 and is an efficient way of using clinicians' time. Ideally, treatment would involve a combination of individual and group treatment. Continuous psychoeducation delivered in a BPSA sensitive way is an integral component of treatment. Psychoeducation has to be both general (up-to-date evidence-based information about SSD and IA should be given to all these patients) and personally tailored (information relevant to the patient's cur rent concerns and level of readiness). The following 2. Helping the patient change the relationship with his or her body from fear and avoidance to awareness and acceptance 3. Increasing emotional awareness and learning effective ways of emotional expression and regulation 4. Learning to recognize emotional cues from the body S. Increasing level of physical activity (in physical therapy, mind-body groups, and so forth) 6. Improving functioning and interpersonal well-being, and decreasing isolation Psychosomatic interventions can continue beyond symptom alleviation to minimize the risk of somatic symptoms/IA relapse. When somatic symptoms fl are up, previously successful treatments may be restarted.
For patients with moderate to severe somatic symptoms/IA, referral for specialized outpatient or inpatient psychosomatic treatment is warranted. In the multidisciplinary approach, the primary care team stays involved, following up with the patient and partic ipating in the psychosomatic center case conferences.
CONCLUSIONS
SSD and IA are challenging yet possible to treat. See Box 16.4 for a review of the evidence which support our approach. Integrating primary care and psycho somatic/mental health treatment, using a stepped care approach, helping patients develop full BPSA, meeting their relational needs, and .hanging the culture of the primary care clinics to promote full BPSA can lead to significant relief of patients' suffer ing. Implementation of this approach within health care systems will also decrease burnout and increase the sense of fulfillment among health care profes sionals. Reorganization of health care systems to adopt the BPSA-informed multidisciplinary model is needed to improve treatment ofSSD and IA and to increase the cost-effectiveness of health care at both hospital and societal levels. These approaches have been used successfully in several countries. Given the personal and financial burden of SSD and IA on individuals, health care providers, and society, and the fact that integrated care has been demonstrated to be feasible and effective, it behooves health care policy planners and health care system leaders to accept the challenge to reshape the approach to care of those with SSD and IA.
